Oncology

Back to articles

Vemurafenib: Targeted therapy for melanoma

KEY POINT

Vemurafenib (Zelboraf—Hoffmann-La Roche), an oral targeted therapy, improved survival in patients with previously untreated melanoma with the BRAF V600E mutation. FDA approved the agent in August 2011. A companion diagnostic test, one used to identify patients whose tumors have the mutation, was also approved.

SOURCES

Chapman PB et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–16.